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AN UPDATE ON THE CURRENT STATUS OF THE DENGUE VACCINE
Mia Tuang Koh
Department of Paediatrics, Faculty of Medicine, University of Malaya, Kuala Lumpur
Dengue disease represents a growing global threat with an estimated more than 
2.5 billion people are at risk, representing more than 40% of the world population. 
WHO estimates that there are between 50-100 million dengue infections 
worldwide annually, another 500,000 cases of severe dengue infection with a 
large proportion of whom are children and about 2.5% of those affected died. This 
significant disease burden has made the development of an effective vaccine a 
global health priority.
After nearly 30 years of clinical development and research an effective dengue 
vaccine has yet to be developed. The first live, attenuated tetravalent dengue 
vaccine was developed at the Mahidol University in collaboration with Aventis-
Pasteur in the late 1990s. Phase 1 trial on human volunteers showed preferential 
viraemia with DEN3 virus and the vaccine was most reactogenic. Since then, 
newer techniques in the development of a dengue vaccine has enabled a number 
of manufacturers competing to produce the first dengue vaccine which is not 
only immunogenic, less reactogenic but efficacious in preventing all four dengue 
serotypes. Several of the competitors have now reached different phases of 
clinical trials with the Sanofi Pasteur live, attenuated, chimeric, Yellow fever-
Dengue tetravalent vaccine (CYD-TDV) in the forefront of the race completing 
phases IIb and III of the clinical trials. The vaccine is a recombinant, chimeric 
vaccine based on the 17D yellow fever virus as its backbone. 
Together with the Thai government Sanofi Pasteur had just completed phase IIb 
efficacy trial (CYD23) of its tetravalent dengue vaccine in 2009. The study involved 
4002 healthy children aged 4-11years and was carried out in the Ratchaburi 
district of Thailand. The results have since been published online in the Lancet in 
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Human enteroviruses usually cause self-limited disease except polioviruses 
and enterovirus 71 (EV71) which frequently cause neurological complications 
in young children. Due to successful immunization programs, polioviruses are 
almost eliminated globally. In the contrast, EV71 has recently caused cyclical 
fatal epidemics in tropical Asia and development of EV71 vaccines has become 
national priority in several Asia countries. Several vaccine candidates including 
live-attenuated virus, inactivated whole virus, recombinant proteins, virus-like 
particles, and nucleic vaccines have been developed and tested in animals. Based 
on successful experience with inactivated poliovirus vaccines, inactivated EV71 
whole virus vaccine candidates are most desirable and five vaccine candidates 
are being evaluated in clinical trials in China, Taiwan and Singapore. All of these 
vaccine candidates are inactivated whole virus vaccines but different cell lines 
and virus genotypes were employed in different organizations. Clinical safety 
and immunogenicity of several vaccine candidates have been published recently. 
This presentation will review these data. Moreover, this talk will also discuss 
international networks for enterovirus surveillance and vaccine quality which are 
critical to conduct multi-nation clinical trials and the licensure of EV71 vaccines.    
and perianal abscess (49%), lymphadenitis (42%) and recurrent diarrhea (30%). 
Aspergillosis and salmonellosis occurred at a frequency similar to published 
studies (13% and 19% respectively), but the commonest infection was BCG (43%) 
and 11% had disseminated BCG. 21% of patients had tuberculosis. Fulminant 
melioidosis and Chromobacterium violaceum infections occurred in 3 patients 
and two of their male siblings. Hyperinflammatory conditions included polyarthritis 
(n=3) and pulmonary granuloma (n=2). Death was recorded in 8 patients (15%). 
Conclusion: Melioidosis and C. violaceum indigenous to Southeast Asia can cause 
life-threatening infections in CGD patients. The high incidence of mycobacterial 
infections is associated with universal BCG vaccination and endemicity of 
tuberculosis. Such observations emphasize the role of respiratory burst as an 
immune defense mechanism against these pathogens. These infections are 
seldom reported in Caucasian cohorts, illustrating the importance of regional 
collaborative studies to facilitate pattern recognition and early diagnosis of 
primary immunodeficiencies.
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UNIQUE PATTERN OF INFECTIONS IN CHRONIC 
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Background: Chronic granulomatous disease (CGD) is a phagocytic disorder 
caused by defective NADPH oxidase activity. Affected individuals are susceptible 
to bacterial infections, mycosis and hyperinflammatory complications. Variations 
in the epidemiology of infectious diseases across geographical regions can lead 
to distinct clinical phenotypes.
Objective: To identify the unique clinical characteristics of a large cohort of CGD 
patients in China and Southeast Asia referred for genetic studies from 2003 to 
2012. 
Methods: 53 patients with genetically-confirmed CGD were included and their 
clinical features were analyzed. CYBB and CYBA mutations were studied by 
Sanger sequencing, and NCF1 ‘GT’ deletion hotspot mutation was studied on 
genomic DNA by GeneScan. 
Results: 44 patients with X-CGD had CYBB mutations (missense[n=16]; 
nonsense[n=8]; deletion[n=9]; insertion[n=2]; intron mutation[n=9]). Nine 
patient had AR-CGD (CYBA[n=5]; NCF1 75_76delGT[n=4]). The median age at 
presentation and diagnosis was higher in AR-CGD (7m and 66m) compared with 
X-CGD (3m and 22m). The commonest presentations were pneumonia (58%), skin 
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